<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02378662</url>
  </required_header>
  <id_info>
    <org_study_id>MG-EP-RF-03</org_study_id>
    <nct_id>NCT02378662</nct_id>
  </id_info>
  <brief_title>TARGTEPO Treatment for Anemia in End Stage Renal Disease (ESRD) Patients Undergoing Peritoneal Dialysis (PD)</brief_title>
  <official_title>Safety &amp; Efficacy of Prolonged Physiologic Erythropoietin (EPO) Level Treatment of Anemia in End Stage Renal Disease (ESRD) Patients Undergoing Peritoneal Dialysis (PD)Using MDGN201 TARGTEPO</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aevi Genomic Medicine, LLC, a Cerecor company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medgenics Medical Israel Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Aevi Genomic Medicine, LLC, a Cerecor company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to assess safety and to evaluate the biologic activity of
      TARGTEPO treatment in Peritoneal Dialysis patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase II, open-label study. Each patient will receive targeted dose of
      Erythropoietin (EPO) delivered via TARGTEPO.

      The targeted doses will be determined according to 2 cohorts as follows: Group A (18-25
      IU/Kg/day), Group B (35-45 IU/Kg/day). The objective is to evaluate safety and biologic
      activity of TARGTEPO treatment when maintaining Hb levels within the target range of 9-12
      g/dl. Biological activity assessments will include duration of TARGTEPO secretion as measured
      by serum EPO levels above baseline.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor's decision of the Early Termination of the study.
  </why_stopped>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patients Who Achieved Biological Activity of MDGN201 TARGTEPO Secretion as Measured by Serum Erythropoietin (EPO) Levels Above Baseline</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Anemia of End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MDGN201 TARGTEPO secreting EPO (18-25 IU/Kg/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MDGN201 TARGTEPO secreting EPO (35-45 IU/Kg/day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MDGN201 TARGTEPO</intervention_name>
    <description>MDGN201 TARGTEPO secreting EPO</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject diagnosed with Anemia due to Chronic Renal Failure CKD stage 5 on peritoneal
             dialysis treatment for at least 6 months. Average Hb during last month between 9 to
             12g/dL.

          2. Kt/V &gt;1.

          3. INR ≤1.2

          4. Serum albumin &gt;3.2

          5. Subjects with adequate iron stores (transferrin saturation &gt; 20.0% and/or ferritin
             &gt;100 ng/ml).

        Exclusion Criteria:

          1. Uncontrolled hypertension (defined as diastolic blood pressure &gt; 110 mmHg or systolic
             blood pressure &gt; 180 mmHg during screening).

          2. Subjects who receive oral anti-coagulation treatment (e.g. warfarin)

          3. Subjects who receive Acetyl Salicylic Acid (ASA) above 325 mg/day or patients who
             receive ASA treatment between 100mg/d and 325 mg/d who cannot discontinue it for 1
             week prior to each Harvest or Implantation procedure

          4. Congestive heart failure (New York Heart Association functional class III or IV).

          5. Grand mal seizures within 2 years of the screening visit.

          6. Clinical evidence of severe hyperparathyroidism as defined by PTH levels of &gt; 10 times
             the upper normal limits.

          7. Major surgery within 12 weeks of the screening visit.

          8. Systemic hematologic diseases (e.g., sickle cell anemia, thalassemia (excluding
             Thalassemia minor), myelodysplastic syndromes, hematologic malignancy, myeloma,
             hemolytic anemia).

          9. Current systemic infection, active inflammatory disease, or malignancy under active
             treatment.

         10. Subjects known to have tested positive at any time in the past for antibodies to
             erythropoietic proteins.

         11. Subject has history of malignancy within the past 2 years prior to the screening
             visit, with the exception of basal cell carcinoma.

         12. Subjects with other concurrent severe and/or uncontrolled medical condition which
             could compromise participation in the study (i.e. active infection, uncontrolled
             diabetes, uncontrolled hypertension, congestive heart failure, unstable angina,
             ventricular arrhythmias, active ischemic heart disease, myocardial infarction within
             six months, uncompensated cirrhosis, active upper GI tract ulceration).

         13. Subject is currently enrolled in, or has not yet completed a period of at least 30
             days or five half-lives of the investigational drug whichever is longer, since ending
             other investigational device or drug trial(s) prior to Screening phase.

         14. Psychiatric, addictive, or any other disorder that compromises ability to provide
             informed consent for participation in this study.

         15. Female subjects of child-bearing potential and males that do not agree to use
             acceptable methods of contraception during the study.

         16. Pregnant and lactating female subjects.

         17. Chronic alcoholic or drug abuse subjects.

         18. Steroid or other immunosuppressive treatment (other than topical or inhaled steroids).

         19. Subjects unwilling or unable to comply with the study procedures.

         20. EPO Naïve subjects.

         21. Known sensitivity to Gentamycin and Amphotericin

         22. History of chronic or active Hepatitis B and/or C infection or positive serology at
             screening and known positive HIV or positive serology at screening.

         23. Subject had blood transfusion within 84 days prior to Screening visit.

         24. Subject has a date for renal transplantation.

         25. Refer to the USPI - Depo-Medrol - Methylprednisolone Acetate - Injectable (Appendix A)
             for any concomitant drug taken by the patient which its interaction with Depo-Medrol
             will warrant exclusion from this protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shany Blum, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Medgenics Medical Israel Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barzili Medical Center</name>
      <address>
        <city>Ashkelon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Assaf Harofeh Medical Center</name>
      <address>
        <city>Zrifin</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <study_first_submitted>February 22, 2015</study_first_submitted>
  <study_first_submitted_qc>February 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2015</study_first_posted>
  <results_first_submitted>July 18, 2017</results_first_submitted>
  <results_first_submitted_qc>December 18, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 19, 2018</results_first_posted>
  <last_update_submitted>December 18, 2017</last_update_submitted>
  <last_update_submitted_qc>December 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peritoneal Dialysis</keyword>
  <keyword>End Stage Renal Disease</keyword>
  <keyword>Anemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Early phase and small feasibility study.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group A</title>
          <description>18-25 IU/Kg/day</description>
        </group>
        <group group_id="P2">
          <title>Group B</title>
          <description>35-45 IU/Kg/day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Harvesting</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Implantation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Early Discontinuation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent to Treat (ITT) Population</population>
      <group_list>
        <group group_id="B1">
          <title>Group A</title>
          <description>18-25 IU/Kg/day</description>
        </group>
        <group group_id="B2">
          <title>Group B</title>
          <description>35-45 IU/Kg/day</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Patients Who Achieved Biological Activity of MDGN201 TARGTEPO Secretion as Measured by Serum Erythropoietin (EPO) Levels Above Baseline</title>
        <time_frame>52 weeks</time_frame>
        <population>No statistical analysis was performed as only two subjects were treated with MDGN201 TARGTEPO due to Sponsor's decision to discontinue study.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>18-25 IU/Kg/day</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>35-45 IU/Kg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Who Achieved Biological Activity of MDGN201 TARGTEPO Secretion as Measured by Serum Erythropoietin (EPO) Levels Above Baseline</title>
          <population>No statistical analysis was performed as only two subjects were treated with MDGN201 TARGTEPO due to Sponsor's decision to discontinue study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group A</title>
          <description>18-25 IU/Kg/day</description>
        </group>
        <group group_id="E2">
          <title>Group B</title>
          <description>35-45 IU/Kg/day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction to ciprofloxacin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Catheter exit site infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intermittent Muscle cramps in both legs</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Swelling in right groin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Redness in right groin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Should the investigator wish to publish the results of this study, the investigator agrees to provide Medgenics with a manuscript for review 60 days prior to submission for publication. Medgenics retains the right to delete from the manuscript information that is confidential and proprietary and to object to suggested publication and/or its timing (at the Company’s sole discretion).</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Garry A. Neil, MD</name_or_title>
      <organization>Aevi Genomic Medicine</organization>
      <phone>610-254-4208</phone>
      <email>garry.neil@aevigenomics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

